Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price shot up 6% during trading on Wednesday . The stock traded as high as $13.60 and last traded at $13.59, with a volume of 214,075 shares trading hands. The stock had previously closed at $12.82.

Several brokerages have commented on RVNC. Zacks Investment Research upgraded shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Wednesday, July 13th. Brean Capital reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Thursday, June 23rd. SunTrust Banks Inc. dropped their price target on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, June 14th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $35.00 price target (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Guggenheim restated a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a research report on Tuesday, June 14th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $39.60.

The company’s market capitalization is $398.81 million. The firm has a 50 day moving average of $13.55 and a 200 day moving average of $17.41.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.12. During the same period last year, the business earned ($0.65) EPS. On average, analysts anticipate that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

Other institutional investors recently added to or reduced their stakes in the company. Jennison Associates raised its position in Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 603 shares during the period. California State Teachers Retirement System raised its position in Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 5,492 shares during the period. Finally, Russell Frank Co bought a new position in Revance Therapeutics during the fourth quarter valued at approximately $1,384,000.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.